· Regulation · Regulation Desk
PCAC recommended BPC-157, KPV, TB-500, MOTS-C, Semax, and Epitalon for the 503A bulks list in July 2026. Weeks on, FDA has issued no decision, and commentators are questioning whether a binary yes-or-no framework fits the peptide class.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.